Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy

Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica J., Kayani, Jehanzeb, Fisher, Ann, Kotansky, Brian, Dembry, Louise-Marie, Datta, Rupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726471/
https://www.ncbi.nlm.nih.gov/pubmed/36483361
http://dx.doi.org/10.1017/ash.2022.229
Descripción
Sumario:Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died.

Ejemplares similares